# Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections

> **NCT02134301** · PHASE1 · COMPLETED · sponsor: **Melinta Therapeutics, LLC** · enrollment: 41 (actual)

## Conditions studied

- Gram-positive Bacterial Infections

## Interventions

- **DRUG:** Oritavancin

## Key facts

- **NCT ID:** NCT02134301
- **Lead sponsor:** Melinta Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2025-11-04
- **Final completion:** 2025-11-04
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02134301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02134301, "Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02134301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*